Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Fluad Quadrivalent, Fluarix Quadrivalent, Fluzone High-Dose Quadrivalent, Fluzone Quadrivalent
Generic Name
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)
DrugBank Accession Number
DB16588
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Fluad QuadrivalentInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus, Inc.2020-02-212022-07-31US flag
Fluarix Quadrivalent 2021/2022Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2021-07-022022-06-30US flag
FLUARIX TETRA SUSPENSION FOR INJECTIONInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 mcg/0.5ml) + Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated) (15 mcg/0.5ml) + Influenza B virus B/Colorado/06/2017 live (attenuated) antigen (15 mcg/0.5ml) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 mcg/0.5ml)Injection, suspensionIntramuscularGLAXOSMITHKLINE PTE LTD2015-03-23Not applicable
FLUZONE High-Dose Quadrivalent Northern HemisphereInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (60 ug/0.7mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (60 ug/0.7mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-07-022022-06-30US flag
Fluzone QuadrivalentInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-07-022022-06-30US flag
Fluzone QuadrivalentInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-07-022022-06-30US flag
Fluzone QuadrivalentInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-07-022022-06-30US flag
Fluzone Quadrivalent Southern HemisphereInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-02-042021-12-31US flag
Fluzone Quadrivalent Southern HemisphereInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-02-042021-12-31US flag
Fluzone Quadrivalent Southern HemisphereInfluenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2021-02-042021-12-31US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
WD5E5VYM2E
CAS number
Not Available

References

General References
Not Available
RxNav
2479040

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Injection, suspensionIntramuscular15 mcg/0.5ml
Injection, suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at February 13, 2021 17:37 / Updated at February 15, 2021 18:49